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Formyl peptide receptors (FPRs) play an essential role in the regulation of endogenous inﬂammation and
immunity. In the present studies, a large series of pyridazin-3(2H)-one derivatives bearing an arylace-
tamide chain at position 2 was synthesized and tested for FPR agonist activity. The pyridazin-3(2H)-one
ring was conﬁrmed to be an appropriate scaffold to support FPR agonist activity, and its modiﬁcation at
the 4 and 6 positions led to the identiﬁcation of additional active agonists, which induced intracellular
Ca2þ ﬂux in HL-60 cells transfected with either FPR1, FPR2, or FPR3. Seven formyl peptide receptor 1
(FPR1)-speciﬁc and several mixed FPR1/FPR2 dual agonists were identiﬁed with low micromolar EC50
values. Furthermore, these agonists also activated human neutrophils, inducing intracellular Ca2þ ﬂux
and chemotaxis. Finally, molecular docking studies indicated that the most potent pyridazin-3(2H)-ones
overlapped in their best docking poses with fMLF and WKYMVM peptides in the FPR1 and FPR2 ligand
binding sites, respectively. Thus, pyridazinone-based compounds represent potential lead compounds for
further development of selective and/or potent FPR agonists.
 2013 Elsevier Masson SAS. Open access under CC BY-NC-ND license.1. Introduction
Formyl peptide receptors (FPRs) are chemoattractant receptors
belonging to the seven transmembrane domain G protein-coupled
receptor (GPCR) family known to couple to pertussis toxin (PTX)-
sensitive Gi proteins [1]. FPRs play an important role in the regu-
lation of inﬂammatory reactions and cellular dysfunction and are
expressed in the majority of white blood cells, such as neutrophils,
monocytes and dendritic cells. In humans, there are three FPR
isoforms [2], including FPR1 (formyl peptide receptor 1) and FPR2
(formyl peptide receptor 2), which exhibit 69% amino acidic ho-
mology to each other, and FPR3 (formyl peptide receptor 3) with
56% amino acid sequence identity to FPR1 and 83% to FPR2. FPR1
was ﬁrst identiﬁed in the early 1970s as a high-afﬁnity binding site
on the surface of neutrophils for N-formyl peptides, such as the
prototypic fMLF (formyl-methionine-leucine-phenylalanine) [3]. In
addition to FPR1, neutrophils also express the closely related FPR2,.P. Giovannoni).
 under CC BY-NC-ND license.which is a low-afﬁnity receptor for fMLF, despite the relatively high
level of sequence homology with FPR1. These two receptors have a
similar distribution in a variety of different tissues and cells
involved in inﬂammation, such as endothelial cells, platelets and
dendritic cells. Moreover, FPR2 is also expressed in a range of other
cell types, including phagocytic leukocytes, hepatocytes, epithelial
cells, T lymphocytes, neuroblastoma cells, astrocytoma cells, and
microvascular endothelial cells [4]. Unlike FPR1 and FPR2, FPR3
does not bind N-formyl peptides and is expressed in neutrophils,
but it is speciﬁcally expressed on monocytes and dendritic cells [5].
FPRs interact with a large number of structurally distinct ligands,
and their activation induces a variety of complicated downstream
signaling responses involved in inﬂammatory processes, such as
chemotaxis, degranulation, and superoxide generation [6]. FPR
activation has also been associated with various diseases, including
ischemia-reperfusion injury [7], prion disease [8], amyloidosis,
Alzheimer’s disease [9], HIV [10], stomach ulcer [11], some cancers
[12], and nociception associated with inﬂammatory processes [13].
Numerous receptors modulate the host inﬂammatory
response, and resolution of inﬂammation involves the formation
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Fig. 1. Representative modiﬁcations performed on the pyridazin-3(2H)-one derivatives.
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for the proper functioning of host cells. FPRs interact with some
resolving mediators (e.g., lipoxins) and have clearly emerged as
crucial players in important endogenous anti-inﬂammation pro-
cesses essential to ensure regulation and control of inﬂammation
in order to avoid self-induced damage [14]. Thus, FPRs represent a
promising new target for the discovery of novel anti-
inﬂammatory and pro-resolving drugs able to selectively stimu-
late the innate immune response or endogenous anti-
inﬂammation systems [6]. Indeed, there is an evidence that
bioactive ligands acting as FPR agonists might play a role as useful
therapeutics in host defense and as immunomodulatory activa-
tors that are able to enhance selective innate immune responses
in order to reduce detrimental effects associated with inﬂam-
mation and infectious diseases [15].
Based on our previous results demonstrating the suitability of
pyridazin-3(2H)-one as anappropriate scaffold for FPRagonists [16],
as well as evidence from the literature that both FPR-speciﬁc [17,18]
and mixed FPR1/FPR2 agonists [19,20] are of potential interest for
treatment of diseases involving neutrophilic inﬂammation, we
performed further modiﬁcations on this chemotype in order to
evaluate if these modiﬁcations would increase the potency and/or
selectivity of the agonists. Since we already showed that an acet-
amide side chain as well as the presence of lipophilic and/or elec-
tronegative substituents in the aryl group at the end of the chaina
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Scheme 1. Synthesis of pyridazin-3(2H)-one derivatives 6aew. Reagents and conditions: a)
5% (w/v) in anhydrous EtOH, 1e3 h, reﬂux; c) ethyl bromoacetate (1.5 equiv), K2CO3 (2 equiv)
(1.1 equiv), Et3N (3.5 equiv), substituted aniline (2 equiv), anhydrous THF, 12 h, 5 C/rt; (fwere essential for activity at position 2 of the pyridazin-3(2H)-one
[16], we performed several modiﬁcations at the C-4, C-5, and C-6
positions of the ring, as these modiﬁcations have not been well
studied previously (Fig. 1). For example, we eliminated the methyl
group at position 6 and then increased the steric hindrance and/or
modiﬁed the electronic characteristics of the substituents by intro-
ducing (substituted) aromatic and heteroaromatic systems. In
addition, we evaluated the role of position 4 by changing or
removing the substituents at the benzyl fragment and changing the
phenyl ring with various heterocyclic rings. These new agonists
were evaluated for their ability to activate intracellular Ca2þ mobi-
lization and chemotaxis in human neutrophils and their binding to
FPR1 and FPR2 was evaluated by molecular docking studies.
2. Chemistry
As extensively reported in the literature, g-keto acids are the
common starting material to easily generate dihydropyridazinone
scaffolds [21,22], which are the key building blocks for the synthesis
of the pyridazinone class of compounds outlined in Schemes 1
and 2. With the exception of compounds 1aec, which were syn-
thesized following published procedures [23e25], all other g-keto
acids (1dek) were purchased from commercial sources.
Condensation of the appropriate g-keto acid with hydrazine
hydrate resulted in the previously described C-6 substitutedR
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Scheme 3. Synthesis of pyridazin-3(2H)-one derivative 18. Reagents and conditions: a)
CAN (3 equiv), CH3COOH 50%, 1.5 h, 60 C; b) N-(4-bromophenyl)-2-chloroacetamide
[38] (1.5 equiv), K2CO3 (2 equiv), anhydrous CH3CN, 6 h, reﬂux.
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Scheme 2. Synthesis of pyridazin-3(2H)-one derivatives 11aeq and 15a,b. Reagents and conditions: a) substituted benzaldehyde (1 equiv), KOH 5% (w/v) in anhydrous EtOH, 1e5 h,
reﬂux; b) ethyl bromoacetate (1.5 equiv), K2CO3 (2 equiv), anhydrous CH3CN, 2e4 h, reﬂux; c) NaOH 6 N, 1e5 h, 80 C; d) ethyl chloroformate (1.1 equiv), Et3N (3.5 equiv),
substituted aniline (2 equiv), anhydrous THF, 12 h, 5 C/rt; e) N-(4-bromophenyl)-2-chloroacetamide [38] (1.5 equiv), K2CO3 (2 equiv), anhydrous CH3CN, 2e3 h, reﬂux; f) POCl3,
3 h, 60 C; g) SeO2 (3 equiv), anhydrous EtOH, 5e7 h, reﬂux.
M.P. Giovannoni et al. / European Journal of Medicinal Chemistry 64 (2013) 512e528514dihydropyridazinones 2aeh,j,k [21,26e32] and the new 2i in good
yields (Scheme 1). A further synthetic step was required to obtain
compound 2l, which was generated by melting and spontaneous
decarboxylation of the carboxylic acid 2k at 160 C [33]. The C-6
modiﬁed pyridazinones 6aew (Scheme 1) were then prepared in
four steps starting from the dihydropyridazinones 2aej,l. The
previously described intermediates 3h,j,l [34] and the new 3ae
g,i,k,mep were obtained through a Knoevenagel condensation
with the commercially available 3- or 4-methoxybenzaldehyde in
the presence of KOH. Subsequent alkylation with ethyl bromoace-
tate gave esters 4aep, which were transformed into the corre-
sponding carboxylic acids 5aep by alkaline hydrolysis under
standard conditions. Reaction of the intermediates 5aepwith ethyl
chloroformate in the presence of triethylamine in THF resulted in
the intermediate mixed anhydrides, which were transformed in
good yields into the ﬁnal amides 6aew by treatment with the
appropriate aryl amines (Scheme 1).
Scheme 2 shows the synthesis of compounds 11aeq, where the
3- or 4-methoxybenzyl moiety at the C-4 position of the pyr-
idazinone ring was eliminated or replaced by several heterocyclic
and substituted benzyl groups. The dihydropyridazinone 7 [16] was
converted into the previously described derivatives 8hej [35e37]
and the new 8aeg,k,l by Knoevenagel condensation with the
appropriate aromatic aldehyde in the presence of KOH. Subse-
quently, compounds 8aej were ﬁrstly alkylated with ethyl bro-
moacetate to give the esters 9aej, of which 9j was previously
reported [37], and then hydrolyzed under basic conditions to give
the new carboxylic acid derivatives 10aej. These intermediates
were transformed into the ﬁnal amides 11ael (Scheme 2) from the
corresponding mixed anhydrides by performing the same reactionas described above for intermediates 6aew. A different synthetic
procedure was required to obtain compounds 11meo (Scheme 2).
Intermediates 8k,l and 8m, obtained from 8l by dehydration of the
amide with phosphorus oxychloride, were unstable to strong base
treatment and were directly converted into compounds 11meo by
alkylation under standard condition with the previously described
N-(4-bromophenyl)-2-chloroacetamide [38]. Furthermore, com-
pounds 15a,b (Scheme 2) were obtained in good yields by carrying
out the usual reaction sequence (alkylation/hydrolysis/amide bond
formation) described above, starting alternatively with dihy-
dropyridazinone 7 [16] and its pyridazinone derivative 12 [31,39],
which was obtained by using selenium dioxide as the oxidizing
agent. Moreover, the synthesis of compounds 11p,q, which contain
a 4-iodophenylacetamide chain at position 2, was carried out
starting from 15a and using Knoevenagel condensation with the
appropriate aromatic aldehyde (Scheme 2).
Scheme 3 shows the synthesis of the 4-arylketone derivative 18,
which was prepared from 16 [16] by oxidation of the benzylic
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Scheme 4. Synthesis of pyridazin-3(2H)-one derivatives 23, 27 and 28aec. Reagents and conditions: a) ethyl bromoacetate (1.5 equiv), K2CO3 (2 equiv), anhydrous CH3CN, 3 h,
reﬂux; b) 4-methoxyphenylboronic acid (2 equiv), Cu(OAc)2 (1.5 equiv), Et3N (2 equiv), CH2Cl2, 12 h, rt; c) NaOH 6N, 1e2 h, 80 C; d) ethyl chloroformate (1.1 equiv), Et3N (3.5 equiv),
4-bromoaniline (2 equiv), anhydrous THF, 12 h, 5 C/rt; e) HBr 48%, 1 h, 140 C; f) for 28a: 4-methoxyphenylboronic acid (1 equiv), Cu(OAc)2 (1.5 equiv), Et3N (2 equiv), CH2Cl2, 12 h,
rt; for 28b,c: substituted benzoyl chloride (2.4 equiv), Et3N (catalytic), anhydrous CH2Cl2, 16 h, 0 C/rt.
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quent alkylation under standard conditions with the previously
described intermediate N-(4-bromophenyl)-2-chloroacetamide
[38].
The synthetic pathway for compounds 23, 27 and 28aec is
shown in Scheme 4. The 4-amino-5-acetyl pyridazinone 19 [40]
and its derivative 24 [41], obtained by deacetylation of 19 using
48% hydrobromic acid under pressure at high temperature (140 C)
[42], were previously described. Starting from compound 19 and
following alkylation with ethyl bromoacetate (20), coupling on the
amine at C-4 was performed using 4-methoxyphenylboronic acid
in the presence of Cu(Ac)2 in CH2Cl2. The intermediate 21was then
processed by standard alkaline hydrolysis and coupling with 4-
bromoaniline, through the intermediate mixed anhydride, to
obtain the ﬁnal amide 23 in good yield. Alternatively, compound 24
was directly processed by standard alkylation, hydrolysis, and
amidation to generate the ﬁnal 4-amino derivative 27 (Scheme 4).
Subsequently, coupling of the amine group of 27 with 4-
methoxyphenylboronic acid in the presence of Cu(Ac)2 gave the
C-4 arylamine 28a, while the C-4 arylamide analogs 28b,c were
obtained from 27 by treatment with the opportune arylchloride
and triethylamine in CH2Cl2 at 0 C.O
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Scheme 5. Synthesis of pyridazin-3(2H)-one derivative 33. Reagents and conditions: a) NH2
(2 equiv), anhydrous CH3CN, 1.5 h, reﬂux; c) NaOH 6N, 0.5 h, 60 C; d) ethyl chloroformateThe synthesis of compound 33 with a 4-methoxyphenyl group
directly bonded to C-4 of the pyridazinone ring is shown in
Scheme 5. Condensation of the known g-keto ester 29 [43] with
hydrazine hydrate resulted in intermediate 30, which was sub-
jected to the usual alkylation/alkaline hydrolysis/amidation steps to
obtain the ﬁnal amide 33 in good yield (Tables 1e4).
3. Pharmacology
In the present study, we synthesized a library of 49
pyridazinone-based compounds, which were screened in order to
identify novel small-molecule FPR agonists. The compounds were
evaluated for their ability to induce intracellular Ca2þ ﬂux in human
HL-60 cells transfected with FPR1, FPR2, or FPR3 [44,45]. Since
undifferentiated HL-60 cells do not express any FPRs and do not
respond to FPR agonists, we evaluated all compounds in non-
transfected HL-60 cells to verify that the observed activity was
speciﬁc for the individual FPRs expressed. Both EC50 values and
relative efﬁcacy were determined (Tables 5e7) and compared to
the peptide agonists fMLF and WKYMVm, as well as to reference
compounds AeD, which were previously designated as 14m, 14x,
14e, and 14a, respectively [16].N N
O
O
O
NH Br
N N
O
O
O
OH
32 33
dc
NH2 (2 equiv), anhydrous toluene, 2 h, reﬂux; b) ethyl bromoacetate (1.5 equiv), K2CO3
(1.1 equiv), Et3N (3.5 equiv), 4-bromoaniline (2 equiv), anhydrous THF, 12 h, 5 C/rt.
Table 1
Legend for intermediates 1, 2aek.
Compds 1, 2 R
a CH2CH3
b CH(CH3)2
c C6H11
d C6H5
e 2-Thienyl
f C6H4eCH3 (p)
g C6H4eOCH3 (p)
h C6H4eCl (p)
i C6H4eF (p)
j CH2eC6H5
k COOH
Table 3
Legend for intermediates 8ael.
Compds 8 R
a C6H5
b C6H4eF (m)
c C6H4eCl (m)
d C6H4eBr (m)
e C6H3e(OCH3)2 (m, m)
f C6H4eCF3 (p)
g 3-Furyl
h 3-Thienyl
i 2-Thienyl
j 1-Naphthyl
k 3-Pyridyl
l C6H4eCONH2 (p)
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4.1. Biological results
SAR analysis at position C-6 of the pyridazinone ringwas used to
investigate modiﬁcation of the methyl group of the previously re-
ported series of compounds [16] (Fig. 1), including (a) elimination
or replacement with superior homologs; (b) introduction of the
cyclohexyl group; (c) introduction of the 2-thienyl group; (d)
introduction of (substituted) aryl groups; and (e) introduction of
the benzyl group (Table 5). As shown in Table 5, elimination of the
methyl group led to the active but relatively non-selective com-
pound 6a, which was able to activate all three FPR subtypes. The
ethyl analog (6b) displayed increased selectivity in comparison
with reference compound C (Table 5) and exhibited very similar
behavior to the reference bromo-derivative B (Table 5), whereas the
isopropyl analog (6c) resulted a mixed agonist for FPR1, FPR2 and
FPR3. In contrast, introduction of a cyclohexyl group at position C-6
(6d) was associated with FPR1 selectivity (EC50 ¼ 10.8 mM). Among
compounds having a phenyl group at C-6 (6eeg), only 6e, which
contains Br in the phenylacetamide chain, was active and was a
mixed FPR1/FPR2 agonist. The 2-thienyl derivatives 6hej were
completely inactive, as were the benzyl derivative 6w and all
compounds containing OCH3 (6kem), Cl (6nep), CH3 (6qes), and F
(50tev) in the para position of the phenyl ring at C-6 of the pyr-
idazinone nucleus. It is worth noting that the complete inactivity of
the 4-F analog 6t, in comparisonwith compound 6e (EC50 ¼ 9.0 mM
at FPR1 and 4.3 mM at FPR2), suggests that for these derivatives,
electronic features play a more important role than steric
properties.
SAR studies at position C-4 were performed by modifying the
reference compounds AeD [16] using the following criteria: (a)Table 2
Legend for intermediates 3e5aep.
Compds 3e5 R OCH3
a H m
b CH2CH3 m
c CH(CH3)2 m
d C6H11 m
e C6H5 m
f 2-Thienyl p
g 2-Thienyl m
h C6H4eOCH3 (p) p
i C6H4eOCH3 (p) m
j C6H4eCl (p) p
k C6H4eCl (p) m
l C6H4eCH3 (p) p
m C6H4eCH3 (p) m
n C6H4eF (p) p
o C6H4eF (p) m
p CH2eC6H5 pelimination of the OCH3 substituent on the benzyl group; (b)
introduction of different substituents in the meta or para posi-
tions of the benzyl group; (c) replacement of the methoxybenzyl
with heterocycles; (d) complete elimination of the C-4 substitu-
ent; (e) introduction of different functionalized linkers; and (f)
elimination of the CH2-spacer of the benzyl group (Tables 6 and
7). In comparison to reference compound D [16], when OCH3
group was eliminated from the benzyl fragment at position C-4 of
the pyridazinone scaffold (11a), activity was decreased, particu-
larly as an FPR2 agonist (Table 6). The concomitant presence of an
unsubstituted benzyl at C-4 and F (11b) or methylenedioxy (11c)
in the arylacetamide side chain was associated in the ﬁrst case
with complete loss of activity and in the latter case with selective
FPR1 agonist activity (EC50 ¼ 6.9 mM) (Table 6). On the other
hand, replacement of the 3-methoxy group on the benzyl at po-
sition C-4 with different substituents was beneﬁcial. In fact,
replacement of OCH3 with F or Cl (Table 6, reference compound
D) in the meta position resulted in compounds 11d and 11e,
which were selective FPR1 agonists (EC50 ¼ 6.6 and 10.5 mM,
respectively). Conversely, the chloro analog (11q) of reference
compound C, which contains a 4-iodophenyl in the acetamidic
spacer of position 2, had decreased activity and efﬁcacy as a
mixed FPR1/FPR2 agonist. Unexpectedly, introduction of a Br (11f)
in place of the OCH3 group on the benzyl at C-4 was associated
with complete loss of activity. These data suggest that the pres-
ence of a substituent of limited hindrance in the meta position is
an essential requirement for binding to FPR1 and FPR2. Moreover,
insertion of an additional methoxy group in reference compound
D was associated with complete loss of activity (11g), whereas the
3,5-dimethoxybenzyl derivative 11p, which contains a 4-
iodophenyl in the acetamidic spacer at position 2, exhibited
weak, but speciﬁc FPR1 activity (Table 6, reference compound C).
Introduction of CF3 (11h), CONH2 (11n), and CN (11o) in the para
position was generally detrimental (Table 6).
Useful information originated by replacement of the methox-
yphenyl group at C-4 with 5- and 6-membered heterocycles.Table 4
Legend for intermediates 9, 10aej.
Compds 9,10 R
a C6H5
b C6H4eF (m)
c C6H4eCl (m)
d C6H4eBr (m)
e C6H3e(OCH3)2 (m, m)
f C6H4eCF3 (p)
g 3-Furyl
h 3-Thienyl
i 2-Thienyl
j 1-Naphthyl
Table 5
Activity of compounds 6aew (Scheme 1) in HL-60 cells expressing human FPR1, FPR2, or FPR3.
N
N
O
R
O
NH
OCH3R1
Compd. R OCH3 R1 Ca2þ mobilization
EC50 (mM) and efﬁcacy (%)a
FPR1 FPR2 FPR3 W.T.b
A16 CH3 m 3,4-Methylenedioxy 2.3 (50) N.A. N.A. N.A.
B16 CH3 p Br (p) N.A. 2.4 N.A. N.A.
C16 CH3 m I (p) 2.8 (90) 6.8 (40) 13.0 (30) N.A.
D16 CH3 m Br (p) 3.4 (75) 3.8 (70) N.A. N.A.
6a H m Br (p) 6.1 (125) 7.7 (60) 14.6 (25) N.A.
6b CH2CH3 m I (p) 4.2 (70) 5.5 (65) N.A. N.A.
6c CH(CH3)2 m Br (p) 4.5 (135) 7.2 (90) 17.4 (30) N.A.
6d C6H11 m Br (p) 10.8 (80) N.A. N.A. N.A.
6e C6H5 m Br (p) 9.0 (110) 4.3 (25) N.A. N.A.
6f C6H5 m 3,4-Methylenedioxy N.A. N.A. N.A. N.A.
6g C6H5 m F (p) N.A. N.A. N.A. N.A.
6h 2-Thienyl p Br (p) N.A. N.A. N.A. N.A.
6i 2-Thienyl m 3,4-Methylenedioxy N.A. N.A. N.A. N.A.
6j 2-Thienyl m F (p) N.A. N.A. N.A. N.A.
6k C6H4eOCH3 (p) p Br (p) N.A. N.A. N.A. N.A.
6l C6H4eOCH3 (p) m 3,4-Methylenedioxy N.A. N.A. N.A. N.A.
6m C6H4eOCH3 (p) m F (p) N.A. N.A. N.A. N.A.
6n C6H4eCl (p) p Br (p) N.A. N.A. N.A. N.A.
6o C6H4eCl (p) m 3,4-Methylenedioxy N.A. N.A. N.A. N.A.
6p C6H4eCl (p) m F (p) N.A. N.A. N.A. N.A.
6q C6H4eCH3 (p) p Br (p) N.A. N.A. N.A. N.A.
6r C6H4eCH3 (p) m 3,4-Methylenedioxy N.A. N.A. N.A. N.A.
6s C6H4eCH3 (p) m F (p) N.A. N.A. N.A. N.A.
6t C6H4eF (p) p Br (p) N.A. N.A. N.A. N.A.
6u C6H4eF (p) m 3,4-Methylenedioxy N.A. N.A. N.A. N.A.
6v C6H4eF (p) m F (p) N.A. N.A. N.A. N.A.
6w CH2eC6H5 p Br (p) N.A. N.A. N.A. N.A.
a N.A., no activity (no response was observed during ﬁrst 2 min after addition of compounds under investigation) considering the limits of efﬁcacy> 20% and EC50< 50 mM.
b W.T., wild-type non-transfected HL-60 cells. The EC50 values are presented as the average mean of three independent experiments, in which EC50 values were determined
by nonlinear regression analysis of the doseeresponse curves (5e6 points) generated using GraphPad Prism 5with 95% conﬁdential interval (p< 0.05). Efﬁcacy (in brackets) is
expressed as % of the response induced by 5 nM fMLF (FPR1) or 5 nM WKYMVm (FPR2 and FPR3).
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weak selectivity for FPR1, as did both the thienyl (11j,k) and pyridyl
(11m) analogs, which had similar activity proﬁles without receptor
subtype-selectivity (Table 6). In contrast, insertion of a naph-
thylmethyl (11l) in position C-4 was associated with decreased
activity but increased selectivity for FPR1. The unsubstituted de-
rivatives at C-4 in the pyridazinone ring 15a,b, which contains 4-
iodophenyl in the acetamidic spacer at position 2, were
completely devoid of activity (Table 6).
Introduction of a carbonyl group in the place of CH2 of the
benzyl group at position 4 of the pyridazinone ring resulted in
compound 18, which was a potent mixed FPR1/FPR2 agonist
(Table 7, reference compound D). When CH2 was replaced by NH in
both compound 23 and the 5-acetyl analog 28a (reference com-
pound B), agonist activity was found mainly at FPR2, whereas
compound 27 was a less potent FPR2 agonist. Substitution of CH2
with an amidic group in 28bwas detrimental for FPR1, but not FPR2
activity, whereas analog 28cwas totally inactive. Lastly, elimination
of the methylenic linker resulted in a selective FPR1 agonist (33).
It should be noted that all FPR1/FPR2/FPR3 agonists were inac-
tive in wild-type non-transfected HL-60 cells (Tables 5e7), sup-
porting the speciﬁcity of our assays.
Twenty compounds that showed the best agonist proﬁles in
transfected cells were selected for evaluation as chemotactic agentsand for their ability to induce Ca2þ mobilization in human neu-
trophils. All compounds had EC50 values in the micromolar range
and an efﬁcacy range of 70e130% (Table 8). The most active com-
pounds were 6c and 6e, which had EC50 values of 0.85 and 0.6 mM
for inducing Ca2þ ﬂux and EC50 values of 0.70 and 0.60 mM for
inducing chemotaxis, respectively. Representative kinetic curves of
Ca2þ mobilization and doseeresponse for chemotactic activity for
the phenyl derivative 6e are shown in Fig. 2. It is interesting to note
that among the tested compounds, there were mixed FPR1/FPR2/
FPR3 agonists (6a, 6c,11k), dual FPR1/FPR2 agonists (6b, 6e,11i,11j,
11m, 18, 23, 27, 28a, 28b) and selective FPR1 agonists (6d, 11cee,
11p, 33), suggesting that FPR1 is important for Ca2þ mobilization
and chemotaxis in human neutrophils.
Although our functional assays suggested that all active com-
pounds were relatively non-toxic, we evaluated the potential
cytotoxic effects of the pyridazin-3(2H)-one derivatives (both
active and inactive compounds) to determine if the results might be
inﬂuenced by background toxicity. Using a cytotoxicity assay, we
determined that none of the compounds signiﬁcantly affected
viability of wild-type HL-60 cells over a concentration range of 5e
20 mM, verifying that these compounds were not toxic to these
cells, at least during entire incubation period used in the Ca2þ ﬂux
and chemotaxis assays. As examples, effects of the 20 active com-
pounds on cell viability are shown in Fig. 3.
Table 6
Activity of compounds 11aeq and 15a,b (Scheme 2) in HL-60 cells expressing human FPR1, FPR2, or FPR3.
N N
O
O H
N
R1
N N
O
O H
N
R 15a11a-q
N N
O
O H
N
15b
II
Compd. R R1 Ca2þ mobilization
EC50 (mM) and efﬁcacy (%)a
FPR1 FPR2 FPR3 W.T.b
A16 C6H4eOCH3 (m) 3,4-Methylenedioxy 2.3 (50) N.A. N.A. N.A.
B16 C6H4eOCH3 (p) Br (p) N.A. 2.4 N.A. N.A.
C16 C6H4eOCH3 (m) I (p) 2.8 (90) 6.8 (40) 13.0 (30) N.A.
D16 C6H4eOCH3 (m) Br (p) 3.4 (75) 3.8 (70) N.A. N.A.
11a C6H5 Br (p) 5.5 (50) 11.6 (20) N.A. N.A.
11b C6H5 F (p) N.A. N.A. N.A. N.A.
11c C6H5 3,4-Methylenedioxy 6.9 (55) N.A. N.A. N.A.
11d C6H4eF (m) Br (p) 6.6 (110) N.A. N.A. N.A.
11e C6H4eCl (m) Br (p) 10.5 (100) N.A. N.A. N.A.
11f C6H4eBr (m) Br (p) N.A. N.A. N.A. N.A.
11g C6H3e(OCH3)2 (m, m) Br (p) N.A. N.A. N.A. N.A.
11h C6H4eCF3 (p) Br (p) N.A. N.A. N.A. N.A.
11i 3-Furyl Br (p) 5.8 (100) 6.3 (75) N.A. N.A.
11j 3-Thienyl Br (p) 4.5 (100) 14.1 (65) N.A. N.A.
11k 2-Thienyl Br (p) 8.1 (140) 11.4 (60) 10.2 (25) N.A.
11 l 1-Naphthyl Br (p) 13.8 (20) N.A. N.A. N.A.
11m 3-Pyridyl Br (p) 9.3 (85) 2.8 (90) N.A. N.A.
11n C6H4eCONH2 (p) Br (p) 29.3 (40) 27.2 (80) N.A. N.A.
11o C6H4eCN (p) Br (p) N.A. N.A. N.A. N.A.
11p C6H3e(OCH3)2 (m, m) I (p) 7.6 (80) N.A. N.A. N.A.
11q C6H4eCl (m) I (p) 9.5 (55) 16.9 (35) N.A. N.A.
15a e e N.A. N.A. N.A. N.A.
15b e e N.A. N.A. N.A. N.A.
a N.A., no activity (no response was observed during ﬁrst 2 min after addition of compounds under investigation) considering the limits of efﬁcacy> 20% and EC50< 50 mM.
b W.T., wild-type non-transfected HL-60 cells. The EC50 values are presented as the average mean of three independent experiments, in which EC50 values were determined
by nonlinear regression analysis of the doseeresponse curves (5e6 points) generated using GraphPad Prism 5with 95% conﬁdential interval (p< 0.05). Efﬁcacy (in brackets) is
expressed as % of the response induced by 5 nM fMLF (FPR1) or 5 nM WKYMVm (FPR2 and FPR3).
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To explore the possibility that the novel FPR1/FPR2 agonists
could bind to the fMLF binding site of FPR1 and the WKYMVM
binding site of FPR2, we used a previously published homology
model of FPR1 [46,47] and also constructed a model of FPR2 by
homology modeling using the Phyre2 server, since the crystal
structure models of FPR1 and FPR2 are still unavailable. Both
models are based on bovine rhodopsin (see Experimental section).
It should be noted that slightly higher sequence identity between a
given target and template alone does not always justify the choice
of GPCR structure for the optimal homology modeling template,
and additional considerations are important [48]. In the present
modeling studies, the rhodopsin-based model of FPR2 was selected
as the most predictive structure from 18 other homology models,
based on 8 dissolved crystal structures of GPCRs, including bovine
and squid rhodopsins, human adenosine receptor A2A, turkey b1
adrenoceptor, human b2 adrenoceptor, human histamine receptor
H1, human dopamine D3 receptor, and human chemokine receptor
CXCR4. Although the CXCR4 structure has a higher sequence
identity with FPR2 (28%), this structure has lower resolution (3.2A)
for the template, as compared to the rhodopsin structure (2.2 A).
Our recent modeling experiments showed that the geometric
conﬁguration of the FPR2 binding site in the rhodopsin-based
model is in good agreement with the shape of the hydrophobic
ﬁeld obtained for the FPR2 agonist pharmacophore, which was
obtained by independent modeling [49]. Importantly, therhodopsin-based model of FPR1 effectively differentiated agonists
from inactive compounds [47], and the binding structure of fMLF to
the model is not in conﬂict with experimental evidence reported
before by Mills et al. [50] and has a high similarity with the binding
mode of AC-QAWF [46]. Thus, we feel that these features justify use
of this model as a template for the docking of new FPR1 agonists vs.
the other known GPCR crystal structures currently available.
The best docking poses of selected FPR1 agonists 6d,11d, and 18,
as well as previously published reference compounds A and D [16],
to key sub-areas of the FPR1 binding site [47] are shown in Fig. 4.
Molecular skeletons within the binding site are located mainly
along cavity B and directed to channels A and C or to cavity E, in
accordance with binding modes for 2-arylacetamide pyridazin-
3(2H)-ones. Noticeably, bromine-substituted compounds, in their
best poses, had p-bromophenyl groups located in the vicinity of
channel A and directed outside the binding site. Such an orientation
could be required by the large volume and high hydrophobicity of
bromo-substituted phenyl ring. Additionally, H-bonding in-
teractions of Thr265with the pyridazine nitrogen atom are found in
agonists 6d, 18, and reference compound D, or with the carbonyl
group of the pyridazinone moiety in 11m (Fig. 4C). For compound
18, this carbonyl is also H-bonded to both Thr199 and Asn192.
Reference compound A, which contains a benzodioxolane moiety
instead of a p-bromophenyl group, had the opposite binding mode,
with the benzodioxolane protruding into channel C. In its docking
pose, this compound formed a H-bond between one of its endo-
cyclic oxygen atoms and the hydroxyl groups in Thr199 and Asn192.
Table 7
Activity of compounds 18, 23, 27, 28aec, 33 (Schemes 3e5) in HL-60 cells expressing
human FPR1, FPR2, or FPR3.
N
N
O
RO
NH
Br
R1
Compd. R R1 Ca2þ mobilization
EC50 (mM) and efﬁcacy (%)a
FPR1 FPR2 FPR3 W.T.b
B16 CH2eC6H4eOCH3 (p) H N.A. 2.4 N.A. N.A.
D16 CH2eC6H4eOCH3 (m) H 3.4 (75) 3.8 (70) N.A. N.A.
18 COeC6H4eOCH3 (m) H 3.0 (140) 1.0 (110) N.A. N.A.
23 NHeC6H4eOCH3 (p) COCH3 13.5 (75) 1.7 (90) N.A. N.A.
27 NH2 H 8.1 (115) 29.4 (85) N.A. N.A.
28a NHeC6H4eOCH3 (p) H 12.8 (100) 7.8 (110) N.A. N.A.
28b NHCOeC6H4eOCH3 (m) H 9.3 (120) 2.8 (100) N.A. N.A.
28c NHCOeC6H4eBr (p) H N.A. N.A. N.A. N.A.
33 C6H4eOCH3 (p) H 11.2 (55) N.A. N.A. N.A.
a N.A., no activity (no response was observed during ﬁrst 2 min after addition of
compounds under investigation) considering the limits of efﬁcacy > 20% and
EC50 < 50 mM.
b W.T., wild-type non-transfected HL-60 cells. The EC50 values are presented as
the average mean of three independent experiments, in which EC50 values were
determined by nonlinear regression analysis of the doseeresponse curves (5e6
points) generated using GraphPad Prism 5 with 95% conﬁdential interval (p < 0.05).
Efﬁcacy (in brackets) is expressed as % of the response induced by 5 nM fMLF (FPR1)
or 5 nM WKYMVm (FPR2 and FPR3).
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M.P. Giovannoni et al. / European Journal of Medicinal Chemistry 64 (2013) 512e528 519The ligand binding site of FPR2 has a non-symmetric dumb-bell
shape with two cavities different in size, where the smaller cavity
lies deeply in the binding site and is surrounded by residues Val105,
Asp106, Leu109, Phe110, Arg201, Trp254, and Gln258, as described
previously [51] (Fig. 5). The FPR2-speciﬁc peptide agonist
WKYMVM in its best docking pose occupies this cavity with an
indole moiety near the N-terminus of the peptide (Figs. 5 and 6A). A
narrow channel connecting the two cavities is bordered by residuesTable 8
Ca2þ mobilization and chemotactic activity in human neutrophils treated with
selected FPR1/FPRL1 agonists.
Compd. EC50 (mM) and efﬁcacy (%)a
Ca2þ ﬂux Chemotaxis
6a 8.3 (100) 15.9
6b 1.0 (90) 0.71
6c 0.85 (110) 0.70
6d 2.4 (65) 2.5
6e 0.6 (115) 0.60
11c 6.1 (75) 4.2
11d 4.2 (130) 1.9
11e 6.0 (90) 5.0
11i 3.0 (125) 1.5
11j 3.9 (115) 8.7
11k 3.6 (80) 3.9
11m 4.9 (120) 2.8
11p 3.9 (75) 2.1
11q 2.4 (90) 0.49
18 2.3 (115) 0.87
23 3.9 (110) 2.7
27 2.3 (100) 0.8
28a 2.1 (105) 5.9
28b 2.4 (110) 1.9
33 3.0 (70) 2.1
a The data are presented as average mean of three independent experiments with
cells from different donors, in which EC50 values were determined by nonlinear
regression analysis of the doseeresponse curves (5e6 points) generated using
GraphPad Prism 5 with 95% conﬁdential interval (p < 0.05).
1.0×10-7 1.0×10-6 1.0×10-5 1.0×10-4
0.5
[Compound 6e] (M)
Fig. 2. Analysis of chemotactic activity and Ca2þ mobilization in human neutrophils
treated with compound 6e. Panel A. Representative kinetics of Ca2þ mobilization after
treatment with compound 6e or fMLF. Neutrophils were treated with the compound
6e (210 and 620 nM), 5 nM fMLF (positive control), or DMSO vehicle (negative control),
and Ca2þ ﬂux was monitored for the indicated time. Panel B. Human neutrophil
chemotaxis toward the indicated concentrations of compound 6e was determined, as
described under Biological assays. The data are from one experiment that is repre-
sentative of three independent experiments.Phe257, Val260, Ala261, Thr177, Phe178, and Phe180. The larger
cavity of the docking site opens outside the receptor and has a
complex shape. Four residues (Tyr, Val, and bothMet) of the docked
WKYMVM are located in this cavity (Fig. 6A and Insert).
Docking of FPR2 agonists 11m, 18, 23, and 28b, as well as
reference compounds B and D [16], to FPR2 showed that they adopt
conformations that overlap well with the docking pose of
WKYMVM. The bromo-substituted phenyl rings of 11m, 18, 28b,
and reference agonists B and D lie within the smaller cavity found
deep within the binding site (Fig. 6B). The narrow channel contains
an amide fragment adjacent to the p-bromophenyl groups of the
molecules. In addition, the pyridazinone moieties are oriented
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Fig. 3. Evaluation of selected FPR agonist cytotoxicity. Wild-type, non-transfected
human promyelocytic leukemia HL-60 cells were incubated for 60 min at 37 C with
5 mM (open bars), 10 mM (hatched bars), or 20 mM (solid bars) of the indicated com-
pounds, and cell viability was determined using a luminescent cell viability assay kit,
as described. Values are the mean  S.D. of triplicate samples from one experiment,
which is representative of two independent experiments.
Fig. 4. Homology model of the FPR1 binding site with docked peptide fMLF and selected
non-peptide FPR1 agonists with a pyridazin-3(2H)-one scaffold. Panel A. Docking poses of
fMLF (atoms are highlighted by green spheres) and pyridazin-3(2H)-one11d (atoms are not
highlighted). Key sub-areas of the FPR1 binding site are indicated with arrows and include
two channels (A and C), two cavities (B and E), and the bottom (D), as described previously
and [47]. ChannelA is located in the vicinity of Asn192, Thr199, Thr265, Ile268, and Leu271.
Channel C is bounded by Leu101, Val105, Tyr257, Ser287, and Phe291. Cavity B is a curved
groove, locatedbehind thehydrophobic ledge formedby the isobutyl groupof Leu198, and is
restricted by Val160, Leu198, Arg201, Gly202, and Arg205. Large cavity E is located near
Trp91, Trp95, Cys98, and Lys99, between channel C and a larger ledge. The bottom D of the
binding site is bounded by channels A and C and is associated with Ala261, Ala264, and
Val283. Surface coloringwasmadeaccording toelectrostaticproperties,wherebynegatively
and positively charged areas are shown in red and blue, respectively. Panel B. Overlapping
docking poses of fMLF (blue) and pyridazin-3(2H)-ones 6d (red),11d (green),18 (magenta),
and reference compound A [16] (brown). Panel C. Interactions between Thr265 and com-
pound 11m. H-bond is indicatedwith a dashed line. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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overlaid in the same positions. Such an orientation is conditioned
by the possibility of H-bonding of the nitrogen atom in the pyr-
idazine ring, as well as an oxygen or nitrogen atom in the amide
moiety, with the hydroxyl group of Thr177. As an example, speciﬁc
interactions of 18 with Thr177 and Ala261 are shown in Fig. 6C. In
contrast, compound 23 binds to FPR2 in a different manner. This
ligand is positioned entirely in the larger cavity, possibly because of
the presence of an acetyl group, which prevents passage of the
molecule through the narrow channel (data not shown). However,
compound 23 is also H-bonded toThr177 by an acetyl oxygen atom.
Thus, the formation of H-bonds between ligands and Thr177 seems
to play an important role in positioning FPR agonists within the
ligand binding site.
5. Conclusion
Our data conﬁrm that pyridazinone-based compounds are a
relevant chemotype to search for both selective and/or potent FPR
agonists of human neutrophils. The biological results with C-4 and
C-6 derivatives presented herein conﬁrm our previously reported
conclusion that an arylacetamide moiety at N-2 of the scaffold [16]
is essential for agonist activity. Our SAR studies demonstrate that by
manipulating the chemical structure of a series of pyridazinones
(Fig. 1), it is possible to achieve varying potency and selectivity
toward the different FPR subtypes (Tables 5e7). Position C-6
(Table 6) of the pyridazinone ring was not very tolerant to modi-
ﬁcation, and amethyl group is still the substituent that supports the
best results regarding agonist activity, while its elimination or
substitution with a more hindered moiety resulted in a substantial
loss in activity. Conversely, position C-4 (Tables 6 and 7) was more
amenable to chemical manipulation. Indeed, substituted benzyl
groups and heterocycles (e.g., thienyl, piridyl, furyl), as well as
functionalized spacers (e.g., CO, NH), can be productively intro-
duced at this level, retaining good agonist activity. Molecular
docking experiments showed that the most potent pyridazin-
3(2H)-ones overlap in their best docking poses with the docking
poses for fMLF and WKYMVM in the FPR1 and FPR2 ligand binding
sites, respectively. Overall, these pyridazin-3(2H)-ones appear to
efﬁciently interact with the receptor through speciﬁc H-bonding
with Thr265, Thr199 and Asn192 in FPR1 or Thr177 in FPR2.
Fig. 5. Potential areas of FPR2 where ligands of could be docked. A PDB ﬁle of the
homology model for FPR2, based on the bovine rhodopsin template, was loaded into
MVD software, and the “Detect cavity” feature was applied with probe size 1.2 A to
identify potential areas of the receptor where ligands could be docked. Two cavities
were found with volumes of 241 Å3 and 25 Å3 (green zones indicated by arrows). The
binding pose of the FPR2 agonist WKYMVM is shown for comparison (red sticks). The
search space with a sphere radius of 15 A encompassed the WKYMVM molecule, eight
residues belonging to the binding site [51] (His102, Val105, Asp106, Leu109, Trp254,
Phe257, Ser288, Phe292; atoms of the residues are shown as green balls), and most of
the large cavity (dark green sphere). (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
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presented herein, which were modiﬁed at C-4 and C-6 positions,
showed good FPR agonist activity, and some had selectivity among
the three FPR isoforms. Thus, we were able to identify seven FPR1-
selective agonists (6d, 11cee, 11l, 33) and several potent mixed
FPR1/FPR2 dual agonists with EC50 values in the low micromolar
range, including the 4-keto derivative 18 (EC50 ¼ 3.0 mM at FPR1
and 1.0 mM at FPR2).Fig. 6. Homology model of FPR2 with docked WKYMVM peptide and selected pyr-
idazin-3(2H)-ones. Panel A. Best docking pose of WKYMVM peptide (light-blue). The
FPR2 model is shown in ribbon mode. The small docking cavity (green) lies deep
within the binding site and is surrounded by residues Val105, Asp106, Leu109, Phe110,
Arg201, Trp254, and Gln258. Insert: the larger cavity of the docking site showing the
position of side chain tails of the tetrapeptide fragment (YMVM) of WKYMVM. Surface
coloring was made according to electrostatic properties, whereby negatively and
positively charged areas are shown in red and blue, respectively. Panel B. Overlapping
docking poses of WKYMVM (atoms are indicated with green spheres) and pyridazin-
3(2H)-ones (11m, 18, 23, and 28b) and reference compounds B and C [16]. FPR2 res-
idues within 6 A around the smaller cavity are shown. Panel C. Compound 18 docked
into the FPR2 binding site. Residues lying within 3.5 A of the pose are shown. H-bonds
are indicated with dashed lines. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)6. Experimental section
6.1. Chemistry
6.1.1. General
Reagents and starting materials were obtained from com-
mercial sources. Extracts were dried over Na2SO4, and the sol-
vents were removed under reduced pressure. All reactions were
monitored by thin layer chromatography (TLC) using commercial
plates precoated with Merck silica gel 60 F-254. Visualization was
performed by UV ﬂuorescence (lmax ¼ 254 nm) or by staining
with iodine or potassium permanganate. Chromatographic sepa-
rations were performed on a silica gel column by gravity chro-
matography (Kieselgel 40, 0.063e0.200 mm; Merck), ﬂash
chromatography (Kieselgel 40, 0.040e0.063 mm; Merck), silica
gel preparative TLC (Kieselgel 60 F254, 20  20 cm, 2 mm), or a
CombiFlash Rf System (using RediSep Rf Silica Columns, Tele-
dyne Isco, Lincoln, Nebraska, USA). Yields refer to chromato-
graphically and spectroscopically pure compounds, unless
otherwise stated. Compounds were named following IUPAC rules,
as applied by Beilstein-Institut AutoNom 2000 (4.01.305) or CA
Index Name. All melting points were determined on a microscope
hot stage Büchi apparatus and are uncorrected. The identity and
purity of intermediates and ﬁnal compounds were ascertained
through 1H NMR and TLC chromatography. 1H NMR spectra were
recorded with Avance 400 instruments (Bruker Biospin Version
002 with SGU). Chemical shifts (d) are reported in ppm to the
M.P. Giovannoni et al. / European Journal of Medicinal Chemistry 64 (2013) 512e528522nearest 0.01 ppm using solvent as the internal standard. Coupling
constants (J values) are given in Hz and were calculated using
‘TopSpin 1.3’ software rounded to the nearest 0.1 Hz. Mass spectra
(m/z) were recorded on an ESI-TOF mass spectrometer (Bruker
Micro TOF), and reported mass values are within the error limits
of 5 ppm mass units. Microanalyses indicated by the symbols of
the elements or functions were performed with a PerkineElmer
260 elemental analyzer for C, H, and N, and they were within
0.4% of the theoretical values.
6.1.2. General procedures for 2aek
To a stirred solution of the suitable g-keto acid 1aek
(1.00 mmol) in EtOH (2 mL), hydrazine hydrate (1.00 mmol) was
added dropwise. The mixture was heated at 60 C for 1e3 h. After
cooling, the precipitate was collected by suction and puriﬁed by
recrystallization from either toluene or ethanol.
6.1.2.1. 6-(4-Fluorophenyl)-4,5-dihydropyridazin-3(2H)-one [2i].
Yield ¼ 95%; mp ¼ 192e93 C (EtOH); 1H NMR (CDCl3) d 2.64 (dd,
2H, COCH2CH2, J ¼ 1.2 Hz, J ¼ 7.5 Hz), 3.00 (dd, 2H, COCH2CH2,
J ¼ 1.2 Hz, J ¼ 7.5 Hz), 7.13 (qd, 2H, Ar, J ¼ 1.8 Hz, J ¼ 4.7 Hz), 7.72e
7.76 (qd, 2H, Ar, J¼ 0.4 Hz, J¼ 3.1 Hz), 8.51 (exch br s, 1H, NH). Anal.
C10H9FN2O (C, H, N).
6.1.3. General procedures for 3aep
To a solution of KOH in absolute EtOH (8 mL, 5%, w/v), the
appropriate compound 2ael (1.39 mmol) and 3- or 4-
methoxybenzaldehyde (1.39 mmol) were added. The mixture was
reﬂuxed under stirring for 1e3 h. After cooling, the mixture was
concentrated in vacuo, diluted with cold water (10e15 mL), and
acidiﬁed with 2 N HCl. For compounds 3aee,p, the suspension was
extracted with CH2Cl2 (3  15 mL). Removal of the solvent resulted
in the ﬁnal compounds, which were puriﬁed by column chroma-
tography using cyclohexane/ethyl acetate 1:3 (for 3a,p), 1:1 (for
3b,e) and 2:1 (for 3c,d) as eluents. After 1 h stirring in an ice-bath,
compounds 3feo were ﬁltered off by suction from the acidic so-
lutions and recrystallized from ethanol.
6.1.3.1. 4-(3-Methoxybenzyl)pyridazin-3(2H)-one [3a].
Yield ¼ 27%; colorless oil (puriﬁed by column chromatography
using cyclohexane/ethyl acetate 1:3 as eluent); 1H NMR (CDCl3)
d 3.83 (s, 3H, OCH3), 3.92 (s, 2H, C6H4eCH2), 6.81e6.89 (m, 4H, Ar),
7.29 (t, 2H, Ar, J ¼ 7.8 Hz), 7.77 (d, 1H, Ar, J ¼ 4.0 Hz). Anal.
C12H12N2O2 (C, H, N).
6.1.4. General procedure for 4aep
A mixture of the appropriate intermediate 3aep (1.34 mmol),
K2CO3 (2.68 mmol), and ethyl bromoacetate (2.01 mmol) in CH3CN
(8 mL) was reﬂuxed under stirring for 1e3 h. The mixture was then
concentrated in vacuo, diluted with cold water, and extracted with
CH2Cl2 (3  15 mL). The solvent was evaporated in vacuo, and
compounds 4aep were puriﬁed by column chromatography using
cyclohexane/ethyl acetate 2:1 as eluent.
6.1.4.1. Ethyl-2-[5-(3-methoxybenzyl)-6-oxopyridazin-1(6H)-yl]ace-
tate [4a]. Yield ¼ 47%; oil (puriﬁed by column chromatography
using cyclohexane/ethyl acetate 2:1 as eluent); 1H NMR (CDCl3)
d 1.31 (t, 3H, CH2CH3, J ¼ 7.1 Hz), 3.82 (s, 3H, OCH3), 3.91 (s, 2H,
CH2eAr), 4.27 (q, 2H, OCH2CH3, J ¼ 7.2 Hz), 4.92 (s, 2H, NCH2CO),
6.79e6.80 (m, 2H, Ar), 6.83 (d, 2H, Ar, J ¼ 7.8 Hz), 7.28 (t, 1H, Ar,
J ¼ 7.8 Hz), 7.67 (d, 1H, Ar, J ¼ 4.1 Hz). Anal. C16H18N2O4 (C, H, N).
6.1.5. General procedures for 5aep
A suspension of the appropriate intermediate 4aep (1.33 mmol)
in 6 N NaOH (10 mL) was stirred at rt up to 60e80 C for 1e2 h. Themixture was diluted with cold water and acidiﬁed with 6 N HCl.
After 1 h stirring in an ice-bath, the products 5aepwere ﬁltered off
by suction and recrystallized from ethanol.
6.1.5.1. 2-[5-(3-Methoxybenzyl)-6-oxopyridazin-1(6H)-yl]acetic acid
[5a]. Yield ¼ 99.9%; mp ¼ 149e51 C (EtOH); 1H NMR (CDCl3)
d 3.81 (s, 3H, OCH3), 3.91 (s, 2H, CH2eAr), 4.98 (s, 2H, NCH2CO), 6.49
(exch br s,1H, OH), 6.78 (s,1H, Ar), 6.81e6.85 (m, 3H, Ar), 7.28 (t,1H,
Ar, J¼ 7.8 Hz), 7.72 (d, 1H, Ar, J ¼ 4.1 Hz). Anal. C14H14N2O4 (C, H, N).
6.1.6. General procedures for 6aew
To a cooled (5 C) and stirred solution of compound 5aep
(0.60 mmol) in anhydrous tetrahydrofuran (6 mL), Et3N (2.10 mmol)
was added. After 30min, themixturewas allowed towarmup to0 C,
and ethyl chloroformate (0.66 mmol) was added. After 1 h, the
commercially available substituted arylamine (1.20 mmol) was
added. The reaction was carried out at room temperature for 12 h,
then themixturewas concentrated in vacuo, dilutedwith coldwater
(20e30mL), and extractedwith CH2Cl2 (3 15mL). The solvent was
evaporated to obtainﬁnal compounds 6aew, whichwere puriﬁed by
column chromatography using cyclohexane/ethyl acetate 2:1 for
compounds 6b,g, cyclohexane/ethyl acetate 3:1 for compounds 6c,e,
CH2Cl2/CH3OH/NH4OH 96:4:0.4 for compound 6d, cyclohexane/
ethyl acetate 1:1 for compounds 6a,f,i,j,w, and n-hexane/ethyl ace-
tate 3:2 for compound 6h,kev as eluents.
6.1.6.1. N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-6-oxopyridazin-
1(6H)-yl]acetamide [6a]. Yield ¼ 70%; mp ¼ 138e40 C (EtOH); 1H
NMR (DMSO-d6) d 3.73 (s, 3H, OCH3), 3.79 (s, 2H, CH2eAr), 4.90 (s,
2H, NCH2CO), 6.83 (t, 3H, Ar, J ¼ 9.5 Hz), 7.14 (d, 1H, Ar, J ¼ 3.8 Hz),
7.23 (t, 1H, Ar, J ¼ 7.8 Hz), 7.53 (q, 4H, Ar, J ¼ 8.2 Hz), 7.85 (d, 1H, Ar,
J¼ 3.8 Hz), 10.47 (exch br s,1H, NH). ESI-MS calcd. for C20H18BrN3O3,
428.28; found: m/z 429.09 [M þ H]þ. Anal. C20H18BrN3O3 (C, H, N).
6.1.7. General procedures for 8ael
To 12 mL of KOH in absolute EtOH (5%, w/v), compound 7 [16]
(4.46 mmol) and the appropriate substituted aromatic aldehyde
(4.46 mmol) were added (4-cyanobenzaldehydewas used to obtain
compound 8l). The reaction was reﬂuxed under stirring for 3e5 h.
After cooling, the mixture was concentrated in vacuo, diluted with
ice-cold water (20e25 mL), and acidiﬁed with 2 N HCl. The sus-
pension was extracted with CH2Cl2 (3  25 mL). Removal of the
solvent resulted in compounds 8ael, which were puriﬁed by
crystallization in ethanol. For compounds 8e,k, an additional pu-
riﬁcation step was performed by ﬂash column chromatography
using cyclohexane/ethyl acetate 2:1 (for 8e) or NH4OH/EtOH/
CH2Cl2/petroleum ether 4:25:150:50 (for 8k) as eluents.
6.1.7.1. 4-Benzyl-6-methylpyridazin-3(2H)-one [8a].
Yield ¼ 99.9%; mp ¼ 113e15 C (EtOH); 1H NMR (CDCl3) d 2.26 (s,
3H, CH3), 3.92 (s, 2H, CH2), 6.73 (s, 1H, Ar), 7.26e7.33 (m, 3H, Ar),
7.28 (t, 2H, Ar, J ¼ 6.9 Hz). Anal. C12H12N2O (C, H, N).
6.1.8. 4-[(6-Methyl-3-oxo-2,3-dihydropyridazin-4-yl)methyl]
benzonitrile [8m]
A suspension of compound 8l (0.82 mmol) in 5 mL of POCl3 was
stirred at 60 C for 3 h. After cooling, the mixture was concentrated
in vacuo, diluted with ice-cold water (10 mL), and extracted with
CH2Cl2 (3  15 mL). The organic layer was dried (Na2SO4) and
concentrated in vacuo to obtain a yellow solid, which was puriﬁed
by ﬂash column chromatography using CH2Cl2/CH3OH 7:3 as
eluent. Yield ¼ 60%; mp ¼ 213e215 C (EtOH); 1H NMR (CDCl3)
d 2.29 (s, 3H, 6-CH3), 3.96 (s, 2H, CHCCH2), 6.79 (s, 1H, Ar), 7.41 (d,
2H, Ar, J ¼ 7.0 Hz), 7.65 (d, 2H, Ar, J ¼ 6.9 Hz), 10.61 (exch br s, 1H,
NH). Anal. C13H11N3O (C, H, N).
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A mixture of the suitable intermediate 8aej, 7 [16] or 12 [31,39]
(4.50 mmol), K2CO3 (9.00 mmol), and ethyl bromoacetate
(6.75 mmol) in CH3CN (10 mL) was reﬂuxed while stirring for 2e
4 h. The mixture was then concentrated in vacuo, diluted with cold
water, and extracted with CH2Cl2 (3  15 mL). The solvent was
evaporated in vacuo, and compounds 9aej and 13a,bwere puriﬁed
by crystallization from ethanol (compounds 9bed,g) or by ﬂash
column chromatography using cyclohexane/ethyl acetate 1:1 (for
9a,e,f and 13a,b) and cyclohexane/ethyl acetate 2:1 (for 9hej) as
eluents.
6.1.9.1. Ethyl-2-[5-benzyl-3-methyl-6-oxopyridazin-1(6H)-yl]acetate
[9a]. Yield ¼ 98%; oil (puriﬁed by column chromatography using
cyclohexane/ethyl acetate 1:1 as eluent); 1H NMR (CDCl3) d 1.31 (t,
3H, CH2CH3, J¼ 7.2 Hz), 2.22 (s, 3H, 3-CH3), 3.90 (s, 2H, CHCCH2), 4.24
(q, 2H,CH2CH3, J¼7.2Hz), 4.85 (s, 2H,NCH2CO), 6.66 (s,1H,Ar), 7.23e
7.28 (m, 3H, Ar), 7.33e7.37 (m, 2H, Ar). Anal. C16H18N2O3 (C, H, N).
6.1.10. General procedures for 10aej and 14a,b
A suspension of the suitable intermediate 9aej or 13a,b
(4.4 mmol) in 6 N NaOH (10 mL) was stirred at rt up to 80 C for 1e
5 h. The mixture was diluted with ice-cold water and then acidiﬁed
with 6 N HCl. Products 10aej and 14a,bwere ﬁltered off by suction
and recrystallized from ethanol.
6.1.10.1. 2-[5-Benzyl-3-methyl-6-oxopyridazin-1(6H)-yl]acetic acid
[10a]. Yield¼ 92%; mp¼ 120e22 C (EtOH); 1H NMR (CDCl3) d 2.25
(s, 3H, 3-CH3), 3.93 (s, 2H, CHCCH2), 4.94 (s, 2H, NCH2CO), 5.50
(exch br s, 1H, OH), 6.70 (s, 1H, Ar), 7.24e7.32 (m, 3H, Ar), 7.35e7.39
(m, 2H, Ar). Anal. C14H14N2O3 (C, H, N).
6.1.11. General procedures for 11ael and 15a,b
To a cooled (5 C) and stirred solution of the appropriate
compound 10aej or 14a,b (2.06 mmol) in anhydrous tetrahydro-
furan (6 mL), Et3N (7.21 mmol) was added. After 30 min, the
mixture was allowed to warm up to 0 C, and ethyl chloroformate
(2.27 mmol) was added. After 1 h, the appropriately substituted
arylamine (4.12 mmol) was added. The reaction was carried out at
room temperature for 12 h. The mixture was then concentrated in
vacuo, diluted with cold water (20e30 mL), and extracted with
CH2Cl2 (3  15 mL). The solvent was evaporated to obtain ﬁnal
compounds 11ael and 15a,b, which were puriﬁed by column
chromatography using cyclohexane/ethyl acetate 2:1 (for 11a,b,de
f,l), cyclohexane/ethyl acetate 1:1 (for 11c,g,i,j), cyclohexane/ethyl
acetate 1:2 (for 11h), CH2Cl2/CH3OH 9.8:0.2 (for 11k), cyclohexane/
ethyl acetate 1:3 (for 15a) and CH2Cl2/CH3OH 9.9:0.1 (for com-
pound 15b) as eluents.
6.1.11.1. 2-[5-Benzyl-3-methyl-6-oxopyridazin-1(6H)-yl]-N-(4-
bromophenyl)acetamide [11a]. Yield ¼ 47%; colorless oil (puriﬁed
by column chromatography using cyclohexane/ethyl acetate 2:1 as
eluent); 1H NMR (CDCl3) d 2.30 (s, 3H, 3-CH3), 3.93 (s, 2H, CHCCH2),
4.94 (s, 2H, NCH2CO), 6.82 (s, 1H, Ar), 7.24e7.28 (m, 2H, Ar), 7.30e
7.38 (m, 7H, Ar), 9.18 (exch br s, 1H, NH). ESI-MS calcd. for
C20H18BrN3O2, 412.28; found: m/z 413.06 [M þ H]þ. Anal.
C20H18BrN3O2 (C, H, N).
6.1.12. General procedures for 11meo
A mixture of the appropriate compound 8kem (0.79 mmol),
K2CO3 (1.58 mmol) and N-(4-bromophenyl)-2-chloroacetamide
[38] (1.19 mmol) in CH3CN (2 mL), was reﬂuxed under stirring for
2e3 h. The mixture was then concentrated in vacuo and diluted
with cold water. After 1 h stirring in an ice-bath, the precipitatewas
ﬁltered off by suction and puriﬁed by ﬂash column chromatographyusing CH2Cl2/CH3OH/NH4OH 9.5:0.5:0.05 (for 11m), CH2Cl2/CH3OH
9.5:05 (for 11n) or CH2Cl2/CH3OH 9.9:0.1 (for 11o) as eluents.
6.1.12.1. N-(4-Bromophenyl)-2-[3-methyl-6-oxo-5-(pyridin-3-
ylmethyl)-pyridazin-1(6H)-yl] acetamide [11m]. Yield ¼ 61%;
mp ¼ 216e218 C (EtOH); 1H NMR (CDCl3) d 2.30 (s, 3H, 3-CH3),
3.92 (s, 2H, CHCCH2), 4.93 (s, 2H, NCH2CO), 6.86 (s, 1H, Ar), 7.27e
7.33 (m, 5H, Ar), 7.61 (d, 1H, Ar, J ¼ 7.8 Hz), 8.54 (d, 2H, Ar,
J¼ 6.2 Hz), 9.29 (exch br s, 1H, NH). ESI-MS calcd. for C19H17BrN4O2,
413.27; found: m/z 414.05 [M þ H]þ. Anal. C19H17BrN4O2 (C, H, N).
6.1.13. General procedures for 11p,q
To 5 mL of KOH in absolute EtOH (5%, w/v), 15a (0.13 mmol) and
the appropriate substituted aromatic aldehyde (0.13 mmol) were
added. The mixture was reﬂuxed under stirring for 1e5 h. After
cooling, the suspension was concentrated in vacuo, diluted with
ice-cold water (5e10 mL), acidiﬁed with 2 N HCl, and extracted
with CH2Cl2 (3  25 mL). Removal of the solvent resulted in com-
pounds 11p,q, which were puriﬁed by ﬂash column chromatog-
raphy using cyclohexane/ethyl acetate 1:1 as eluent.
6.1.13.1. N-(4-Iodophenyl)-2-[5-(3,5-dimethoxybenzyl)-3-methyl-6-
oxopyridazin-1(6H)-yl]acetamide [11p]. Yield ¼ 30%; mp ¼ 63e
65 C (EtOH); 1H NMR (CDCl3) d 2.30 (s, 3H, 3-CH3), 3.79 (s, 6H, 2
OCH3), 3.87 (s, 2H, CHCCH2), 4.94 (s, 2H, NCH2CO), 6.40 (s, 3H, Ar),
6.82 (s, 1H, Ar), 7.28 (d, 2H, Ar, J¼ 5.7 Hz), 7.58 (d, 2H, Ar, J¼ 8.6 Hz),
9.01 (exch br s, 1H, NH). ESI-MS calcd. for C22H22IN3O4, 519.33;
found: m/z 520.07 [M þ H]þ. Anal. C22H22IN3O4 (C, H, N).
6.1.13.2. N-(4-Iodophenyl)-2-[5-(3-chlorobenzyl)-3-methyl-6-
oxopyridazin-1(6H)-yl]acetamide [11q]. Yield ¼ 25%; mp ¼ 58e
60 C (EtOH); 1H NMR (CDCl3) d 2.33 (s, 3H, 3-CH3), 3.90 (s, 2H,
CHCCH2), 4.94 (s, 2H, NCH2CO), 6.86 (s, 1H, Ar), 7.13e7.16 (m, 1H,
Ar), 7.20 (d, 2H, Ar, J¼ 7.0 Hz), 7.28 (d, 3H, Ar, J¼ 4.2 Hz), 7.52 (d, 2H,
Ar, J ¼ 8.7 Hz), 9.14 (exch br s, 1H, NH). ESI-MS calcd. for
C20H17ClIN3O2, 493.73; found: m/z 494.05 [M þ H]þ. Anal.
C20H17ClIN3O2 (C, H, N).
6.1.14. 4-(3-Methoxybenzoyl)-6-methylpyridazin-3(2H)-one [17]
To a stirred and heated (60 C) suspension of compound 16 [16]
(2.39 mmol) in 15 mL of acetic acid (50%, v/v), Ce(NH4)2(NO3)6
(7.17 mmol) was slowly added over 0.5 h, and the reaction is carried
out at 60 C for an additional 1 h. Themixturewas then dilutedwith
ice-cold water (10 mL) and extracted with CH2Cl2 (15 mL). After
washing with H2O (3  10 mL), the organic layer was evaporated
under vacuum, and the residue was puriﬁed by CombyFlash
(eluent: cyclohexane/ethyl acetate, gradient 1:1 to 1:3).
Yield ¼ 17%; oil (puriﬁed by CombyFlash using a gradient 1:1 to
1:3 of cyclohexane/ethyl acetate as eluent); 1H NMR (CDCl3) d 2.25
(s, 3H, 6-CH3), 3.92 (s, 3H, OCH3), 6.74e6.95 (m, 4H, Ar), 7.31 (t, 1H,
Ar, J ¼ 7.8 Hz), 11.32 (exch br s, 1H, NH). Anal. C13H12N2O3 (C, H, N).
6.1.15. N-(4-Bromophenyl)-2-[5-(3-methoxybenzoyl)-3-methyl-6-
oxopyridazin-1(6H)-yl]acetamide [18]
A mixture of intermediate 17 (0.41 mmol), K2CO3 (0.82 mmol),
and N-(4-bromophenyl)-2-chloroacetamide [38] (0.61 mmol) in
CH3CN (5 mL) was reﬂuxed under stirring for 6 h. The mixture was
then concentrated in vacuo and extracted with CH2Cl2 (3  15 mL).
After removal of the solvent under vacuum, the residue was puri-
ﬁed by ﬂash column chromatography using NH4OH/EtOH/CH2Cl2/
petroleum ether 4:25:150:269 as eluent. Yield ¼ 10%; mp ¼ 176e
177 C (EtOH); 1H NMR (CDCl3) d 2.32 (s, 3H, 3-CH3), 3.82 (s, 3H,
OCH3), 4.92 (s, 2H, NCH2CO), 6.62 (s, 1H, Ar), 6.69 (t, 1H, Ar,
J ¼ 2.1 Hz), 6.74 (d, 1H, Ar, J ¼ 7.5 Hz), 6.85 (dd, 1H, Ar, J ¼ 6.3 Hz,
J ¼ 2.0 Hz), 7.29 (t, 1H, Ar, J ¼ 8.2 Hz), 7.38e7.46 (m, 4H, Ar), 9.10
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m/z 457.05 [M þ H]þ. Anal. C21H18BrN3O4 (C, H, N).
6.1.16. General procedure for 20 and 25
A mixture of the appropriate compound 19 [40] or 24 [41]
(0.80 mmol), K2CO3 (1.60 mmol) and ethyl bromoacetate
(1.20 mmol) in CH3CN (5 mL) was reﬂuxed with stirring for 3 h. The
solvent was removed under vacuum, then the crude mixture was
diluted with cold water (10 mL) and extracted with CH2Cl2
(3  15 mL). The organic layer was dried over Na2SO4 and evapo-
rated in vacuo. Compound 20was puriﬁed by recrystallization from
ethanol, whereas compound 25 was puriﬁed by column chroma-
tography using CH2Cl2/CH3OH 95:5 as eluent.
6.1.16.1. Ethyl-2-[4-acetyl-5-amino-3-methyl-6-oxopyridazin-1(6H)-
yl]acetate [20]. Yield ¼ 44%; mp ¼ 145e46 C (EtOH); 1H NMR
(CDCl3) d 1.32 (t, 3H, CH2CH3, J ¼ 7.2 Hz), 2.53 (s, 3H, 3-CH3), 2.60 (s,
3H, COCH3), 4.27 (q, 2H, OCH2CH3, J¼ 7.2 Hz), 4.83 (s, 2H, NCH2CO),
7.75 (exch br s, 1H, NH). Anal. C11H15N3O4 (C, H, N).
6.1.16.2. Ethyl-2-[5-amino-3-methyl-6-oxopyridazin-1(6H)-yl]ace-
tate [25]. Yield ¼ 71%; oil (puriﬁed by column chromatography
using CH2Cl2/CH3OH 95:5 as eluent). 1H NMR (CDCl3) d 1.30 (t, 3H,
CH2CH3, J ¼ 7.2 Hz), 2.22 (s, 3H, 3-CH3), 4.25 (q, 2H, OCH2CH3,
J¼ 7.2 Hz), 4.84 (s, 2H, NCH2CO), 6.17 (s, 1H, Ar). Anal. C9H13N3O3 (C,
H, N).
6.1.17. Ethyl-2-[4-acetyl-5-(4-methoxyphenylamino)-3-methyl-6-
oxopyridazin-1(6H)-yl]acetate [21]
To the suspension of 20 (0.91 mmol), copper acetate
(1.36 mmol), and 4-methoxyphenylboronic acid (1.82 mmol) in
CH2Cl2 (4 mL), Et3N (1.82 mmol) were added, and the mixture was
stirred at room temperature for 12 h. The suspensionwas extracted
with 15% aqueous ammonia (3  10 mL), and the organic layer was
washedwith water (10mL) and dried over Na2SO4. After removal of
the solvent in vacuo, the residue was puriﬁed by ﬂash column
chromatography using cyclohexane/ethyl acetate 1:3 as eluent.
Yield ¼ 61%; mp ¼ 115e17 C (EtOH); 1H NMR (CDCl3) d 1.34 (t, 3H,
CH2CH3, J ¼ 7.2 Hz), 1.88 (s, 3H, COCH3), 2.14 (s, 3H, 3-CH3), 3.81 (s,
3H, OCH3), 4.29 (q, 2H, OCH2CH3, J ¼ 7.2 Hz), 4.88 (s, 2H, COCH2N),
6.85 (d, 2H, Ar, J¼ 6.7 Hz), 7.04 (d, 2H, Ar, J¼ 8.9 Hz), 7.62 (exch br s,
1H, NH). Anal. C18H21N3O5 (C, H, N).
6.1.18. General procedure for 22 and 26
A suspension of the suitable intermediate 21 or 25
(0.39 mmol) in 6 N NaOH (10 mL) was stirred at rt up to 80 C for
1e2 h. The mixture was diluted with cold water and acidiﬁed
with 6 N HCl. After 1 h stirring in an ice-bath, product 22 was
ﬁltered off by suction and recrystallized from ethanol. For
compound 26, the aqueous phase was evaporated in vacuo. The
crude residue was dissolved in ethanol, and the precipitate was
ﬁltered off. Finally, evaporation of the solvent resulted in crude
compound 26, which was puriﬁed by crystallization from
cyclohexane.
6.1.18.1. 2-[4-Acetyl-5-(4-methoxyphenylamino)-3-methyl-6-
oxopyridazin-1(6H)-yl]acetic acid [22]. Yield ¼ 76%; mp ¼ 104e
06 C (EtOH); 1H NMR (CDCl3) d 1.88 (s, 3H, COCH3), 2.10 (exch br s,
1H, OH), 2.16 (s, 3H, 3-CH3), 3.82 (s, 3H, OCH3), 4.95 (s, 2H,
COCH2N), 6.86 (d, 2H, Ar, J¼ 8.6 Hz), 7.05 (d, 2H, Ar, J¼ 8.6 Hz), 7.62
(exch br s, 1H, NH). Anal. C16H17N3O5 (C, H, N).
6.1.18.2. 2-[5-Amino-3-methyl-6-oxopyridazin-1(6H)-yl]acetic acid
[26]. Yield ¼ 99.9%; mp ¼ 234e36 C (cyclohexane); 1H NMR
(CDCl3) d 2.09 (s, 3H, 3-CH3), 4.62 (s, 2H, NCH2CO), 6.13 (s, 1H, Ar),6.37 (exch br s, 2H, NH2), 6.55 (exch br s, 1H, OH). Anal. C7H9N3O3
(C, H, N).
6.1.19. General procedures for 23 and 27
To a cooled (5 C) and stirred solution of 22 or 26 (0.30 mmol)
in anhydrous tetrahydrofuran (3 mL), Et3N (1.06 mmol) was added.
After 30min, themixturewas allowed towarm up to 0 C, and ethyl
chloroformate (0.33 mmol) was added. After 1 h, 4-bromoaniline
(0.60 mmol) was added, and the reaction was carried out at room
temperature for 12 h. The mixture was then concentrated in vacuo,
diluted with cold water (10 mL), and extracted with CH2Cl2
(3  15 mL). The organic layer was dried over Na2SO4 and the
solvent was evaporated to obtain ﬁnal compounds 23 or 27
respectively, which were puriﬁed by ﬂash column chromatography
using cyclohexane/ethyl acetate 1:1 as eluent.
6 . 1 . 1 9 . 1 . N - ( 4 - B r o m o p h e n y l ) - 2 - [ 4 - a c e t y l - 5 - ( 4 -
methoxyphenylamino)-3-methyl-6-oxopyridazin-1(6H)-yl]acetamide
[23]. Yield ¼ 62%; mp ¼ 210e11 C (EtOH); 1H NMR (CDCl3) d 1.88
(s, 3H, COCH3), 2.19 (s, 3H, 3-CH3), 3.83 (s, 3H, OCH3), 4.97 (s, 2H,
COCH2N), 6.87 (d, 2H, Ar, J¼ 8.9 Hz), 7.05 (d, 2H, Ar, J¼ 8.9 Hz), 7.44
(td, 4H, Ar, J¼ 2.8 Hz, J¼ 6.5 Hz), 7.65 (exch br s, 1H, NH), 8.64 (exch
br s, 1H, NH). ESI-MS calcd. for C22H21BrN4O4, 485.33; found: m/z
486.11 [M þ H]þ. Anal. C22H21BrN4O4 (C, H, N).
6.1.19.2. N-(4-Bromophenyl)-2-[5-amino-3-methyl-6-oxopyridazin-
1(6H)-yl]acetamide [27]. Yield ¼ 50%; mp ¼ 244e45 C (EtOH); 1H
NMR (CDCl3) d 2.27 (s, 3H, 3-CH3), 4.93 (s, 2H, COCH2N), 6.24 (s, 1H,
Ar), 7.42 (s, 4H, Ar), 8.83 (exch br s,1H, NH), 8.64 (exch br s, 1H, NH).
ESI-MS calcd. for C13H13BrN4O2, 337.17; found: m/z 338.02
[M þ H]þ. Anal. C13H13BrN4O2 (C, H, N).
6.1.20. N-(4-Bromophenyl)-2-[5-(4-methoxyphenylamino)-3-
methyl-6-oxopyridazin-1(6H)-yl] acetamide [28a]
To a suspension of 27 (0.36 mmol), copper acetate (0.53 mmol)
and 4-methoxyphenylboronic acid (0.36 mmol) in CH2Cl2 (3 mL),
Et3N (0.72 mmol) was added and the mixture was stirred at room
temperature for 12 h. The suspension was extracted with 15%
aqueous ammonia (3  10 mL), and the organic layer was washed
with 10 mL of water and dried over Na2SO4. After removal of the
solvent under reduced pressure, the residue was puriﬁed by ﬂash
column chromatography using CH2Cl2/CH3OH 9.5:0.5 as eluent.
The analytical sample of compound 28awas obtained from further
puriﬁcation through silica gel preparative TLC (eluent: CH2Cl2/
CH3OH 9.5:0.5). Yield ¼ 10%; mp ¼ 249e51 C (EtOH); 1H NMR
(CDCl3) d 2.26 (s, 3H, 3-CH3), 3.86 (s, 3H, OCH3), 4.97 (s, 2H,
COCH2N), 6.38 (s, 1H, Ar), 6.97 (d, 2H, Ar, J ¼ 8.9 Hz), 7.18 (d, 2H,
Ar, J ¼ 8.9 Hz), 7.35 (exch br s, 1H, NH), 7.44 (dd, 4H, Ar, J ¼ 5.5 Hz,
J ¼ 9.1 Hz), 8.77 (exch br s, 1H, NH). ESI-MS calcd. for
C20H19BrN4O3, 443.29; found: m/z 444.10 [M þ H]þ. Anal.
C20H19BrN4O3 (C, H, N).
6.1.21. General procedures for 28b,c
A solution of compound 27 (0.21 mmol), Et3N (5 drops) and the
appropriate substituted benzoyl chloride (0.25 mmol), in dry
CH2Cl2 (5 mL), was stirred at 0 C for 1 h. Extra benzoyl chloride
(0.25 mmol) was added. The reaction was carried out at 0 C for an
additional 3 h, then at room temperature for 16 h. The mixture was
extracted with 6 N NaOH (3  10 mL), and the organic layer was
washed with water (10mL) and dried over Na2SO4. After removal of
the solvent in vacuo, crude compound 28b was puriﬁed by ﬂash
column chromatography using cyclohexane/ethyl acetate 1:3 as
eluent. In the case of compound 28c, puriﬁcationwas performed by
two consecutive silica gel preparative TLC steps using in both cases
cyclohexane/ethyl acetate 1:2 as eluent.
M.P. Giovannoni et al. / European Journal of Medicinal Chemistry 64 (2013) 512e528 5256.1.21.1. 3-Metoxy-N-{2-[(4-bromophenylcarbamoyl)methyl]-6-
methyl-3-oxo-2,3-dihydro pyridazin-4-yl}benzamide [28b].
Yield¼ 13%; mp¼ 226e28 C (EtOH); 1H NMR (CDCl3) d 2.27 (s, 3H,
6-CH3), 3.89 (s, 3H, OCH3), 4.93 (s, 2H, COCH2N), 4.98 (exch br s, 1H,
NH), 6.24 (s, 1H, Ar), 7.16e7.19 (m, 1H, Ar), 7.39e7.45 (m, 5H, Ar),
7.63 (t, 1H, Ar, J¼ 2.5 Hz), 7.73 (dd,1H, Ar, J¼ 5.3 Hz, J¼ 1.0 Hz), 8.83
(exch br s, 1H, Ar). ESI-MS calcd. for C21H19BrN4O4, 471.30; found:
m/z 472.08 [M þ H]þ. Anal. C21H19BrN4O4 (C, H, N).
6.1.21.2. 4-Bromo-N-{2-[2-(4-bromophenylcarbamoyl)methyl]-6-
methyl-3-oxo-2,3-dihydro pyridazin-4-yl}benzamide [28c].
Yield ¼ 10%; colorless oil (puriﬁed by silica gel preparative TLC
using cyclohexane/ethyl acetate 1:2 as eluent); 1H NMR (CDCl3)
d 2.43 (s, 3H, 6-CH3), 4.98 (s, 2H, COCH2N), 7.44 (s, 4H, Ar), 7.69 (d,
2H, Ar, J¼ 8.6 Hz), 7.82 (d, 2H, Ar, J¼ 8.6 Hz), 8.24 (s, 1H, Ar). ESI-MS
calcd. for C20H16Br2N4O3, 520.17; found:m/z 521.00 [M þ H]þ. Anal.
C20H16Br2N4O3 (C, H, N).
6.1.22. 4-(4-Methoxyphenyl)-6-methylpyridazin-3(2H)-one [30]
To an ice-cold solution of (E)-methyl 2-(4-methoxyphenyl)-4-
oxopent-2-enoate 29 [43] (0.34 mmol) in dry toluene (3 mL), hy-
drazine hydrate (0.68 mmol) was added drop-wise. The solution
was stirred at reﬂux temperature for 2 h. The solvent was evapo-
rated, and ice-cold water (5 mL) was added to the residue. The
aqueous layer was extracted with CH2Cl2 (3  15 mL), and the
combined organic layers were dried over Na2SO4 and evaporated in
vacuo. The crude product was puriﬁed by ﬂash column chroma-
tography (eluent: cyclohexane/ethyl acetate 1:3) to yield 30 as an
amorphous white solid. Yield ¼ 55%; mp ¼ 155e158 C (EtOH); 1H
NMR (CDCl3) d 2.39 (s, 3H, 6-CH3), 3.88 (s, 3H, OCH3), 6.99 (d, 2H, Ar,
J ¼ 8.9 Hz), 7.24 (s, 1H, Ar), 7.86 (d, 2H, Ar, J¼ 8.9 Hz), 10.51 (exch br
s, 1H, NH). Anal. C12H12N2O2 (C, H, N).
6.1.23. Ethyl-2-[5-(4-methoxyphenyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]acetate [31]
A mixture of the intermediate 30 (0.18 mmol), K2CO3
(0.36 mmol), and ethyl bromoacetate (0.28 mmol) in CH3CN (2 mL),
was reﬂuxed under stirring for 1.5 h. The mixture was then
concentrated in vacuo and extracted with CH2Cl2 (3  10 mL). After
removal of the solvent under vacuo, the residue was puriﬁed by
ﬂash column chromatography using cyclohexane/ethyl acetate 1:1
as eluent. Yield ¼ 99.9%; colorless oil (puriﬁed by ﬂash column
chromatography using cyclohexane/ethyl acetate 1:1 as eluent); 1H
NMR (CDCl3) d 1.30 (t, 3H, CH2CH3, J ¼ 7.0 Hz), 2.37 (s, 3H, 3-CH3),
3.92 (s, 3H, OCH3), 4.23 (q, 2H, CH2CH3, J ¼ 7.0 Hz), 4.89 (s, 2H,
NCH2CO), 6.94 (d, 2H, Ar, J ¼ 8.8 Hz), 7.21 (s, 1H, Ar), 7.81 (d, 2H, Ar,
J ¼ 8.8 Hz). Anal. C16H18N2O4 (C, H, N).
6.1.24. 2-[5-(4-Methoxyphenyl)-3-methyl-6-oxopyridazin-1(6H)-
yl]acetic acid [32]
A suspension of the intermediate 31 (0.20 mmol) in 6 N NaOH
(1.5 mL) was stirred at 60 C for 0.5 h. The mixture was diluted with
ice-cold water (1 mL), acidiﬁed with 6 N HCl, and the ﬁnal product
32 was then ﬁltered off by suction and recrystallized from ethanol.
Yield ¼ 99.9%; mp ¼ 202e203 C (EtOH); 1H NMR (CDCl3) d 2.41 (s,
3H, 3-CH3), 3.87 (s, 3H, OCH3), 4.99 (s, 2H, NCH2CO), 6.98 (d, 2H, Ar,
J ¼ 8.8 Hz), 7.26 (s, 1H, Ar), 7.82 (d, 2H, Ar, J ¼ 8.8 Hz). Anal.
C14H14N2O4 (C, H, N).
6.1.25. N-(4-Bromophenyl)-2-[5-(4-methoxyphenyl)-3-methyl-6-
oxo-pyridazin-1(6H)-yl]acetamide [33]
To a cooled (5 C) and stirred solution of compound 32
(0.20 mmol) in anhydrous tetrahydrofuran (2 mL), Et3N
(0.70 mmol) was added. After 30 min, the mixture was allowed to
warm up to 0 C, and ethyl chloroformate (0.22 mmol) was added.After 1 h, 4-bromoaniline (0.40 mmol) was added, and the reaction
was carried out at room temperature for 12 h. Themixturewas then
concentrated in vacuo, diluted with cold water (5 mL), and
extracted with CH2Cl2 (3 10 mL). After removal of the solvent, the
residue was puriﬁed by column chromatography using cyclo-
hexane/ethyl acetate 2:1 as eluent. Yield ¼ 35%; mp ¼ 251e253 C
(EtOH); 1H NMR (CDCl3) d 2.43 (s, 3H, 6-CH3), 3.88 (s, 3H, OCH3),
5.00 (s, 2H, NCH2CO), 7.00 (d, 2H, Ar, J¼ 8.7 Hz), 7.27 (s, 1H, Ar), 7.40
(q, 4H, Ar, J ¼ 9.2 Hz), 7.80 (d, 2H, Ar, J ¼ 8.7 Hz), 9.07 (exch br s, 1H,
NH). ESI-MS calcd. for C20H18BrN3O3, 428.28; found: m/z 429.05
[M þ H]þ. Anal. C20H18BrN3O3 (C, H, N).
6.2. Biological assays
6.2.1. Cell culture
Human promyelocytic leukemia HL-60 cells stably transfected
with FPR1 (HL-60-FPR1), FPR2 (HL-60-FPR2), or FPR3 (HL-60-FPR3)
were cultured in RPMI 1640 medium supplemented with 10% heat-
inactivated fetal calf serum,10mMHEPES,100 mg/mL streptomycin,
100 U/ml penicillin, and G418 (1 mg/mL), as described previously
[16,19,47,49]. Speciﬁcity of FPR expression on these cells was
demonstrated previously, and it has been shown in a number of
studies that these cell lines respond only to receptor subtype-
speciﬁc agonists [44,45,52]. Wild-type HL-60 cells were cultured
under the same conditions, but without G418.
6.2.2. Isolation of human neutrophils
Blood was collected from healthy donors in accordance with a
protocol approved by the Institutional Review Board at Montana
State University. Neutrophils were puriﬁed from the blood using
dextran sedimentation, followed by Histopaque 1077 gradient
separation and hypotonic lysis of red blood cells, as previously
described [53]. Isolated neutrophils were washed twice and
resuspended in HBSS without Ca2þ and Mg2þ (HBSS). Neutrophil
preparations were routinely >95% pure, as determined by light
microscopy, and >98% viable, as determined by trypan blue
exclusion.
6.2.3. Ca2þ mobilization assay
Changes in intracellular Ca2þ were measured with a FlexStation
II scanning ﬂuorometer using a FLIPR 3 calcium assay kit (Molecular
Devices, Sunnyvale, CA) for human neutrophils and HL-60 cells. All
active compounds were evaluated in parent (wild-type) HL-60 cells
for supporting that the agonists are inactive in non-transfected
cells. Human neutrophils or HL-60 cells, suspended in HBSS
containing 10 mM HEPES, were loaded with Fluo-4 AM dye (Invi-
trogen) (1.25 mg/mL ﬁnal concentration) and incubated for 30 min
in the dark at 37 C. After dye loading, the cells were washed with
HBSS containing 10 mM HEPES, resuspended in HBSS containing
10 mM HEPES and Ca2þ and Mg2þ (HBSSþ), and aliquotted into the
wells of a ﬂat-bottomed, half-area-well black microtiter plates
(2105 cells/well). The compound source plate contained dilutions
of test compounds in HBSSþ. Changes in ﬂuorescence were moni-
tored (lex ¼ 485 nm, lem ¼ 538 nm) every 5 s for 240 s at room
temperature after automated addition of compounds. Maximum
change in ﬂuorescence, expressed in arbitrary units over baseline,
was used to determine agonist response. Responses were normal-
ized to the response induced by 5 nM fMLF (Sigma Chemical Co., St.
Louis, MO) for HL-60-FPR1 and neutrophils, or 5 nM WKYMVm
(Calbiochem, San Diego, CA) for HL-60-FPR2 and HL-60-FPR3 cells,
which were assigned a value of 100%. Curve ﬁtting (5e6 points) and
calculation of median effective concentration values (EC50) were
performed by nonlinear regression analysis of the doseeresponse
curves generated using Prism 5 (GraphPad Software, Inc., San
Diego, CA).
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Neutrophils were suspended in HBSSþ containing 2% (v/v) fetal
bovine serum(FBS) (2106 cells/mL), andchemotaxiswasanalyzed in
96-well ChemoTx chemotaxis chambers (Neuroprobe, Gaithersburg,
MD), as previously described [53]. Brieﬂy, lower wells were loaded
with 30 mL of HBSSþ containing 2% (v/v) FBS and the indicated con-
centrations of test compound, DMSO (negative control), or 1 nM fMLF
as a positive control. Neutrophils were added to the upper wells and
allowed tomigrate through the 5.0 mmpore polycarbonatemembrane
ﬁlter for 60min at 37 C and5%CO2. The number ofmigrated cellswas
determined bymeasuring ATP in lysates of transmigrated cells using a
luminescence-based assay (CellTiter-Glo; Promega,Madison,WI), and
luminescence measurements were converted to absolute cell
numbers by comparison of the values with standard curves obtained
with known numbers of neutrophils. The results are expressed as
percentage of negative control and were calculated as follows:
(number of cells migrating in response to test compounds/sponta-
neous cell migration in response to control medium)  100. EC50
valueswere determined by nonlinear regression analysis of the dosee
response curves generated using Prism 5 software.
6.2.5. Cytotoxicity assay
Cytotoxicity was analyzed with a CellTiter-Glo Luminescent Cell
Viability Assay Kit (Promega), according to the manufacturer’s
protocol. Brieﬂy, wild-type non-transfected human promyelocytic
leukemia HL-60 cells were cultured at a density of 3104 cells/well
with tested compounds for 60 min at 37 C and 5% CO2. Following
treatment, the cells were allowed to equilibrate to room tempera-
ture for 30 min, substrate was added, and the samples were
analyzed with a Fluoroscan Ascent FL.
6.3. Molecular docking analysis
The FPR1 homology model was created using the crystal
structure of the bovine rhodopsin receptor, which has a sequence
identity of 20% for 348 aligned residues that correspond to the
seven transmembrane domains, as reported previously [46]. It
should be noted, that the crystal structure of bovine rhodopsin was
successfully applied previously to homology modeling of FPR1
[12,54]. The position of the ligand binding site in these models,
based on cross-linking and mutagenesis studies, was found to be
located in the upper region of a helical bundle comprising trans-
membrane domains (TM) 2, 5, 6, and 7 [50,55] and was recently
supported by docking studies of FPR1 agonists, including peptide
Ac-QAWF [46] and series of non-peptide 2-(benzimidazol-2-
ylthio)-N-phenylacetamides [47].
A PDB ﬁle of the homology model for FPR1 was loaded into the
Molegro Virtual Docker (MVD) program (MVD 2010.4.2, Molegro
ApS). Docking search space was deﬁned as a sphere centered at the
carbonyl carbon of the Ala residue inAc-QAWF [46]. The radius of the
sphere was adopted to be 11 A. This search space encompassed the
whole Ac-QAWF molecule and included, at least partially, the
following 36 residues of FPR1: Trp91, Trp95, Cys98, Lys99, Leu101,
Phe102, Thr103, Val105, Asp106, Phe110, Leu156, Thr157, Leu158,
Pro159, Val160, Ile161, Ile162, Asn192, Val193, Ala196, Met197,
Leu198, Thr199, Val200, Arg201, Gly202, Arg205, Phe206, Tyr257,
Ala261, Ala264, Thr265, Ile268, Arg269, Glu270, and Val283.
For homology modeling of FPR2, the primary amino acid
sequence of FPR2 was submitted to the Phyre2 (Protein Homology/
analogy Recognition Engine V2.0) protein fold recognition server
(http://www.sbg.bio.ic.ac.uk/phyre2) [56]. The server used one
template with known crystal structure for homology modeling per
protein sequence. We obtained 18 predicted protein structure
models with the highest level of conﬁdence, based on dissolved
crystal structures of several GPCRs, including bovine and squidrhodopsins, human adenosine receptor A2A, turkey b1 adrenoceptor,
human b2 adrenoceptor, human histamine receptor H1, human
dopamine D3 receptor, and human chemokine receptor CXCR4. Two
FPR2 homology models were pre-selected from the set of predicted
models. One model, based on the CXCR4 structure, had a maximal
sequence identity of 28%, but with a low crystal structure resolution
of 3.2 A for the template. The second model has a template with
sequence identity of 16%, but the highest resolution crystal structure
(2.2A) known to date for a GPCR. Side chain conformations of eight
residues in FPR2 (His102, Val105, Asp106, Leu109, Trp254, Phe257,
Ser288, Phe292), which were previously identiﬁed as belonging to
the binding site [51], were optimized in both models using the
corresponding module of Molegro software. Since our pre-docking
studies indicated that the rhodopsin-based model gave the best
docking positions for FPR2 agonists that were used previously for
pharmacophore modeling [49,57], we propose that these data
justify use of the bovine rhodopsin structure as a template for the
FPR2 homology model vs. the CXCR4 template. Thus, further
modeling was based on the rhodopsin-based model of the FPR2.
Taking into account the lack of structural information about any
ligandereceptor complex with FPR2, we sought to locate cavities in
the macromolecule obtained by homology modeling in order to
identify the search space for docking. Use of the MVD “Detect
cavity” module with probe size 1.2 A gave two cavities with vol-
umes of 241 and 25 Å3 in the region of the ligand binding site.
Positions of these two cavities obviously reﬂect the dumb-bell
shape of the binding site. Hence, for FPR2, we also chose a spher-
ical search space with a default radius of 15 A centered at the ter-
minus of the larger cavity directed to the smaller one (Fig. 5).
Before docking, structures of the compounds were pre-
optimized using HyperChem software with MMþ force ﬁeld and
saved in Tripos MOL2 format. The ligand structures were then im-
ported into the MVD with the options “Create explicit hydrogens”,
“Assign charges (calculated by MVD)”, and “Detect ﬂexible torsions
in ligands” enabled. Selected molecules were docked into FPR1 and
FPR2 using the search spaces indicated above with a rigid receptor
structure. Ligand ﬂexibility was accounted for with respect to tor-
sion angles auto-detected in MVD. MolDock score functions were
used with a 0.3A grid resolution. The “Internal HBond” option was
activated in the “Ligand evaluation”menuof DockingWizard. Thirty
docking runs were performed for each molecule, while 60 docking
runs were performed for the peptide. The option “Return multiple
poses for each run” was enabled, and the post-processing options
“Energy minimization” and “Optimize H-bonds” were applied after
docking. Similar poses were clustered at a RMSD threshold of 1A.
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